• European Council.

    The vaccine theme is at the center

  • Von der Leyen: "On export vaccines we want reciprocity. I trust AstraZeneca, Ema will clarify"

Share

March 26, 2021 The expected declaration by the European Medicines Agency Ema on anti-Covid vaccines in Europe has arrived "All the vaccines for covid-19 approved in the European Union have shown a positive risk-benefit ratio in the prevention of the disease ".



This is what the Agency underlined today during a public meeting.

"Vaccines - said the executive director of the regulatory body, Emer Cooke - are crucial for our return to a normal life".



The process of "development and approval that would usually take 10 years, thanks to unprecedented mobilization, has compressed to one year, offering us safe and effective vaccines in record time, from which we hope to have a positive impact on the course of the pandemic". 



"We are working with the company" that produces the Sputnik vaccine "to define a timetable that could allow the approval of this vaccine in a timely manner," said Marco Cavaleri, head of EMA's vaccination strategy, during the meeting. public.

Cavaleri recalled that the EMA began the continuous review of the Sputnik at the beginning of March.

"It's an adenovirus-based vaccine, similar to Janssen and AstraZeneca," Cavaleri said. 



"Variants of the virus are emerging and regulators are working to ensure that the necessary updates can be carried out quickly to ensure that the anti-Covid19 vaccines remain effective", Cavalera added, who specified "vaccination remains - however - fundamental. to control the pandemic ".



In Italy, through a new circular of 25 March, the Ministry of Health has sent the update of the consent form for the covid-19 vaccination with the update of the information notes relating to the anti-Covid-19 vaccines Astrazeneca, Moderna and Comirnaty Biontech / Pfizer, prepared by the Italian Medicines Agency Aifa which states that compared to the latest Astrazeneca events we read that "following the administration of the covid-19 Astrazeneca vaccine, a combination of blood clots and low platelet levels has been observed very rarely, in some cases with the presence of bleeding. In some severe cases blood clots have occurred in different or unusual locations as well as excessive clotting or bleeding throughout the body. The most serious cases reported are very rare: about 20 million people in Europe (including the UK) received the vaccine as of March 16, 2021 and EMA found 7 cases of thrombi in multiple blood vessels

gni (disseminated intravascular coagulation, cid) and 18 cases of cerebral thrombosis ".